<DOC>
	<DOCNO>NCT01655888</DOCNO>
	<brief_summary>RATIONAL : Preliminary result fron Study MESOT-TREM-2012 indicate promising activity tremelimumab malignant mesothelioma ( MM ) patient . PURPOSE : The propose study MESOT-TREM-2012 aim explore efficacy intensive schedule treatment tremelimumab 29 MM patient . Subjects receive investigational product every 4 week ( wks ) 6 dos , follow dos every 12 wks confirm disease progression .</brief_summary>
	<brief_title>The Anti-CTLA-4 Monoclonal Antibody Tremelimumab Malignant Mesothelioma</brief_title>
	<detailed_description>Primary endpoint : 1 ) To assess rate objective clinical complete response ( CR ) partial response ( PR ) Secondary endpoint : 1 . To define toxicity profile accord NCI CT-CAE V. 3 2 . To assess overall survival ( OS ) 3 . To estimate disease control rate ( DCR ) ( proportion patient best response CR+PR+SD ) accord modify Recist criterion 4 . To assess progression-free survival treat patient accord modified Recist criterion 5 . To evaluate qualitative quantitative change cellular humoral immune response</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Histologically cytologically confirm MM Have receive one prior systemic chemotherapy platinumbased regimen advance MM Measurable disease , define least 1 unidimensionally measurable lesion &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan ( modify RECIST criterion ) Disease amenable curative surgery No known brain metastasis Age 18 Performance status 02 Life expectancy &gt; 12 week Adequate hematologic , hepatic renal function Platelet count &gt; 75000/mm3 Absolute granulocyte count &gt; 1000/mm3 Hemoglobin &gt; 9 g/dL Bilirubin total &lt; 1.5 x ULN ( Upper limit normal ) , except patient document Gilbert 's syndrome , must total bilirubin &lt; 3.0 mg/dl AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN document liver metastasis present ) Creatinine level &lt; 2mg/dl calculated creatinine clearance &gt; 60 mL/min determine Cockcroft Gault equation . Not pregnant nursing Fertile patient must use effective contraception Patient must willing able provide write informed consent , trial approve institutional review board institution Symptomatic chronic inflammatory autoimmune disease Active hepatitis B C Prior treatment tremelimumab antiCTLA4 antibody antiPD1 , antiPDL1 agent Clinically relevant cardiovascular disease History psychiatric disability , potentially interfere capability give adequate inform consent Uncontrolled active infection Other concurrent chemotherapy , immunotherapy , radiotherapy investigational agent History malignancy except adequately treat basal cell carcinoma squamous cell skin cancer carcinoma cervix , unless patient diseasefree least 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Tremelimumab</keyword>
	<keyword>anti-CTLA-4 monoclonal antibody</keyword>
	<keyword>malignant mesothelioma</keyword>
</DOC>